{"id":13949,"date":"2017-03-14T10:27:10","date_gmt":"2017-03-14T10:27:10","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/"},"modified":"2026-02-11T09:44:31","modified_gmt":"2026-02-11T09:44:31","slug":"keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone","status":"publish","type":"post","link":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/","title":{"rendered":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone."},"content":{"rendered":"

\"\"<\/p>\n

Keapstone<\/a> Therapeutics<\/a> , une nouvelle soci\u00e9t\u00e9 de biotechnologie cr\u00e9\u00e9e par l’Universit\u00e9 de Sheffield et Parkinson’s UK pour d\u00e9velopper de nouveaux m\u00e9dicaments contre la maladie de Parkinson et d’autres maladies neurod\u00e9g\u00e9n\u00e9ratives, et Sygnature Discovery, le plus grand fournisseur ind\u00e9pendant britannique de ressources et d’expertise int\u00e9gr\u00e9es en mati\u00e8re de d\u00e9couverte de m\u00e9dicaments, ont annonc\u00e9 aujourd’hui qu’ils collaboreraient pour d\u00e9couvrir de nouveaux traitements contre la maladie de Parkinson et la scl\u00e9rose lat\u00e9rale amyotrophique (SLA).<\/p>\n

Keapstone Therapeutics s’appuiera sur des recherches pionni\u00e8res men\u00e9es au Sheffield Institute for Translational Neuroscience (SITraN) et sur une collaboration internationale avec l’European Lead Factory. Dans le cadre de ces travaux, le Dr Richard Mead, du SITraN, a d\u00e9couvert de nouvelles petites mol\u00e9cules qui emp\u00eachent l’interaction entre deux prot\u00e9ines, la prot\u00e9ine KEAP1 (Kelch-like ECH-associated protein-1) et le facteur nucl\u00e9aire Nrf2 (Nuclear factor (erythroid-derived 2)-like 2), et qui contribuent ainsi \u00e0 am\u00e9liorer la survie des neurones dans la maladie de Parkinson et la SLA (scl\u00e9rose lat\u00e9rale amyotrophique). En \u00e9troite collaboration avec Sygnature Discovery, Keapstone Therapeutics va d\u00e9sormais optimiser ces mol\u00e9cules afin de d\u00e9velopper des candidats m\u00e9dicaments capables de ralentir, voire de stopper, la progression de ces maladies neurod\u00e9g\u00e9n\u00e9ratives. <\/p>\n

Le Dr Richard Mead de Keapstone Therapeutics a d\u00e9clar\u00e9 : \u00ab Nous sommes ravis de ce nouveau partenariat avec Parkinson’s UK. C’est une excellente opportunit\u00e9 pour nous de poursuivre un programme novateur de d\u00e9couverte de m\u00e9dicaments contre la maladie de Parkinson et la SLA. Nous allons maintenant faire progresser ces mol\u00e9cules vers la prochaine \u00e9tape du d\u00e9veloppement de m\u00e9dicaments avec Sygnature Discovery et Peak Proteins. \u00bb<\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

 <\/p>\n

Le Dr Arthur Roach, directeur de la recherche et du d\u00e9veloppement chez Parkinson’s UK, a d\u00e9clar\u00e9 : \u00ab Keapstone est un projet novateur et une premi\u00e8re mondiale de par sa conception. En collaborant d\u00e8s le d\u00e9but avec Sheffield pour la cr\u00e9ation d’une entreprise de biotechnologie d\u00e9riv\u00e9e, nous pourrons \u00e9tudier et d\u00e9velopper des traitements potentiels contre la maladie de Parkinson avec une intensit\u00e9 sans pr\u00e9c\u00e9dent pour une organisation caritative. Cette nouvelle aventure passionnante n’aurait pas \u00e9t\u00e9 possible sans nos donateurs et partenaires. Nous sommes impatients de partager avec eux les avanc\u00e9es de ce projet. \u00bb<\/p>\n

Le Dr Simon Hirst, fondateur et PDG de Sygnature Discovery<\/a> , a d\u00e9clar\u00e9 : \u00ab Nous sommes ravis de collaborer avec Keapstone Therapeutics et Parkinson’s UK pour d\u00e9couvrir de nouveaux m\u00e9dicaments destin\u00e9s \u00e0 traiter la maladie de Parkinson et d’autres maladies neurod\u00e9g\u00e9n\u00e9ratives. L’approche th\u00e9rapeutique novatrice de Keapstone offre un potentiel consid\u00e9rable pour le d\u00e9veloppement de traitements contre ces maladies invalidantes et, \u00e0 terme, mortelles. Sygnature poss\u00e8de une vaste exp\u00e9rience en mati\u00e8re de recherche et de d\u00e9veloppement de m\u00e9dicaments ciblant les maladies neurod\u00e9g\u00e9n\u00e9ratives et a fait ses preuves en mati\u00e8re de mise au point de candidats m\u00e9dicaments pour les essais cliniques. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":13950,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"category":[817,818],"tags":[],"class_list":["post-13949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-domaines-therapeutiques","category-neuroscience"],"acf":[],"yoast_head":"\nKeapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-14T10:27:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T09:44:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"581\" \/>\n\t<meta property=\"og:image:height\" content=\"161\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"pnpd-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"pnpd-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/\"},\"author\":{\"name\":\"pnpd-admin\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\"},\"headline\":\"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone.\",\"datePublished\":\"2017-03-14T10:27:10+00:00\",\"dateModified\":\"2026-02-11T09:44:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/\"},\"wordCount\":553,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/keapstone-logo-web-1.jpg\",\"articleSection\":[\"Domaines th\u00e9rapeutiques\",\"Neuroscience\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/\",\"name\":\"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/keapstone-logo-web-1.jpg\",\"datePublished\":\"2017-03-14T10:27:10+00:00\",\"dateModified\":\"2026-02-11T09:44:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/keapstone-logo-web-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/keapstone-logo-web-1.jpg\",\"width\":581,\"height\":161},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\",\"name\":\"pnpd-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"caption\":\"pnpd-admin\"},\"sameAs\":[\"http:\\\/\\\/www.sygnaturediscovery.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/","og_locale":"fr_CA","og_type":"article","og_title":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/","og_site_name":"Sygnature","article_published_time":"2017-03-14T10:27:10+00:00","article_modified_time":"2026-02-11T09:44:31+00:00","og_image":[{"width":581,"height":161,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg","type":"image\/jpeg"}],"author":"pnpd-admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"pnpd-admin","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#article","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/"},"author":{"name":"pnpd-admin","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448"},"headline":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone.","datePublished":"2017-03-14T10:27:10+00:00","dateModified":"2026-02-11T09:44:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/"},"wordCount":553,"publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg","articleSection":["Domaines th\u00e9rapeutiques","Neuroscience"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/","name":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone. - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg","datePublished":"2017-03-14T10:27:10+00:00","dateModified":"2026-02-11T09:44:31+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/keapstone-logo-web-1.jpg","width":581,"height":161},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/keapstone-therapeutics-et-sygnature-discovery-collaborent-pour-decouvrir-de-nouvelles-therapies-contre-la-maladie-de-parkinson-et-la-maladie-du-motoneurone\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Keapstone Therapeutics et Sygnature Discovery collaborent pour d\u00e9couvrir de nouvelles th\u00e9rapies contre la maladie de Parkinson et la maladie du motoneurone."}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448","name":"pnpd-admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","caption":"pnpd-admin"},"sameAs":["http:\/\/www.sygnaturediscovery.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/comments?post=13949"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/13949\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/13950"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/tags?post=13949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}